Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Both pemetrexed and erlotinib are second-line treatment options for patients with advanced
non-small cell lung cancer. It is controversial that whether it is necessary to detect
epidermal growth factor receptor (EGFR) mutation status for the EGFR-targeted therapy after
the failure of standard chemotherapy. The role of EGFR gene copy number as a predictive
marker remains controversial. Therefore, we investigate the efficacy of erlotinib and
pemetrexed as second-line therapy in treating in patients with EGFR wild-type and EGFR
FISH-positive advanced lung adenocarcinoma.